CAPÍTULO II. METODOLOGÍA 3
6. Acciones y estrategias de mentorías recomen dadas
7.3. Materiales
Normal=1, Low=2 and High=3
Normal values for males: 37%-47%. Females 35%-45%.
INTERNATIONAL NORMALIZED RATIO. Normal =1, Abnormal=2 Normal 1.00-1.25
UREASE BREATH TEST: Positive=1, Negative=2
63 ENDOSCOPY RESULT
UpperGI Endoscopy...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
64
APPENDIX IV
ENDOSCOPY CONSENT FORM
I……….of………hereby consent to the endoscopy procedure to be carried out on me at LASUTH.
DR ………. has explained the nature of the procedure to me with its benefits and the fact that it is relatively safe. I understand that some complications do occur; however, these are rare. The natures of such complications have been explained to me.
Date: ………..……… Signature or thumbprint:………
Witness name: ……….
I confirm that the above procedure has been explained to the patient and that the patient has confirmed his/her understanding of the explanations to me.
Date: ……….. Signature or thumbprint: ………
Doctor’s signature: ………Date……….
65 APPENDIX V
RESEARCH PICTURES
Image 1:Hiatus hernia
Image 2: Gastricerosions and ulcers.
66 Image 3: Heliprobe and card
Image 4: BreathcardTM
67 Image 5: HelicapTM
68
REFERENCES
1. Wallace J. Non-steroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years. Gastroenterology 1997; 112:1000-1016.
2. Vane JR, Flower RJ, Botting RM. History of aspirin and its mechanism of action. Stroke 1990; 21: Suppl: IV-12.
3. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of non-steroidal anti-inflammatory drugs. N Engl J Med. 1999; 340:1888-1899.
4. Kendall B, Peura D. NSAID-associated gastrointestinal damage and the elderly. Practical gastroenterology 1993; 17:13–29.
5. Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol. 1999(Suppl 56):18-24.
6. Brooks P. COX-2 inhibitors. Aust Prescriber. 2000; 23:30-32.
7. Awofisayo O S, Awofisayo O A, Iferi I I, Akpan O E. The Pattern of Sale and Use of Non-Steroidal Anti- Inflammatory Drugs in Rural and Urban Centres in Nigeria. Trop J Pharm Research.2008; 7(3):1013-1018
8. Akande TM, Ologe MO. Prescription pattern at a secondary health care facility in Ilorin, Nigeria. Ann Afr Med. 2007. 6(4):186-189.
9. Awtry EH, Loscalzo J. Aspirin. Circulation 2000; 101: 1206–1218.
10. Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81–106.
69
11. Rothwell PM, Price JF, Fowkes FG, Zanchetti A, Roncaglioni MC, Tognoni G et al.
Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials.
Lancet2012; 379:1602–1612.
12. Chan FK, Graham DY. Review article: prevention of non-steroidal anti-inflammatory drug gastrointestinal complications–review and recommendations based on risk assessment. Aliment Pharmacol Ther. 2004; 19:1051–1061.
13. Richy F, Bruyere O, Ethgen O, Rabenda V, Bouvenot G, Audran M et al. Time-dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach. Ann Rheum Dis. 2004; 63:759-766.
14. Mills EJ, Wu P, Alberton M, Kanters S, Lanas A, Lester R. Low-dose aspirin and cancer mortality: a meta-analysis of randomized trials. Am J Med. 2012; 125:560-567
15. Cook NR, Lee IM, Zhang SM, Moorthy MV, Buring JE. Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Ann Intern Med. 2013; 159:77-85.
16. Talley NJ, Silverstein MD, Agreus L, Nyren O, Sonnenberg A, Holtmann. AGA technical review: evaluation of dyspepsia. Gastroenterology 1998; 114:582.
17. Lichtenstein DR, Syngal S, Wolfe MM. Non-steroidal anti-inflammatory drugs and the gastrointestinal tract: the double-edged sword. Arthritis Rheum. 1995; 38:5-18.
18. Gutthann SP, Garcia RL, Raiford DS. Individual non-steroidal anti-inflammatory drugs and other risk factors for upper gastrointestinal bleeding and perforation. Epidemiology.
1997; 8:18-24.
70
19. Ofman JJ, MacLean CH, Straus WL, Morton SC, Berger ML, Roth EA et al. A meta-analysis of severe upper gastrointestinal complications of non-steroidal anti-inflammatory drugs. J Rheumatol. 2002; 29:804-812.
20. Langman MJ, Weil J, Wainwright P, Lawson DH, Rawlins MD, Logan RF et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs.
Lancet. 1994; 343:1075-1078.
21. Henry D, Lim LL, Garcia RL, Perez GS, Griffin M, Savage R et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs:
results of a collaborative meta-analysis. BMJ. 1996; 312:1563-1566
22. Griffin M. Epidemiology of non-steroidal anti-inflammatory drug-associated gastrointestinal injury. Am J Med. 1998; 104Suppl 3A:23S–9S.
23. Myers, Richard Leroy. The 100 Most Important Chemical Compounds: A Reference Guide.1st edn. US: Greenwood press. 2007: 10-13. ISBN 978-0-313-33758-1.
24. Valkhoff VE, Sturkenboom MC, Kuipers EJ. Risk factors for gastrointestinal bleeding associated with low-dose aspirin. Best Pract Res Clin Gastroenterol. 2012; 26(2):125–
140.
25. Bhatt DL, Scheiman J, Abraham NS, Elliott M. Antman EM, Chan FKL et al.
ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents.
Circulation. 2008; 118(18):1894–1909.
71
26. Boissonnault WG and Meek PD. Risk factors for anti-inflammatory-drug- or aspirin-induced gastrointestinal complications in individuals receiving outpatient physical therapy services. J Orthop Sports PhysTher. 2002; 32: 510–517.
27. Weil J, Langman MJ, Wainwright P, Lawson DH, Rawlins M, Logan RF et al.
Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ. 1995; 310: 827–830.
28. Laurence D, Carpenter J. A dictionary of pharmacology and allied topics, 2nd edn.
Amsterdam: Elsevier, 1998: 8–9.
29. Singh G, Rosen Ramey D. NSAID-induced gastrointestinal complications: the ARAMIS perspective—1997: Arthritis, Rheumatism, and Aging Medical Information System. J Rheumatol Supp. 1998; 51:8-16.
30. Silverstein FE, Graham DY, Senior JR, Davies HW, Struthers BJ, Bittman RM et al.
Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving non-steroidal anti-inflammatory drugs: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 995; 123:241-249.
31. Abraham NS, El-Serag HB, Johnson ML, Hartman C, Richardson P, Ray WA et al.
National adherence to evidence-based guidelines for the prescription of non-steroidal anti-inflammatory drugs. Gastroenterology. 2005; 129(4):1171–1178.
32. Anonymous CSM update .Non-steroidal anti-inflammatory drugs and serious gastrointestinal adverse reactions. Br Med J. 1986; 292:614.
33. Hazeleman, B L. Incidence of gastropathy in destructive arthropathies. Scand J Rheum.
1986; 29:614–619.
72
34. Wilcox CM, Shalek KA, Cotsonis G. Striking prevalence of over-the-counter nonsteroidal anti-inflammatory drug use in patients with upper gastrointestinal haemorrhage. Arch Intern Med. 1994; 154:42–46.
35. Antithrombotic Trialists Collaboration Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ.2002; 324(7329):71–86.
36. Laine L, Maller ES, Yu C, Quan H, Simon T. Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial.
Gastroenterology 2004; 127: 395–402.
37. Olokoba AB, Olokoba LB, Jimoh AA. Upper gastrointestinal tract bleeding in Ilorin, Nigeria a report of 30 cases. Niger J Clin Pract. 2009; 12:240–244.
38. Rukewe A, Otegbayo J.A, Fatiregun, A. Clinical characteristics and outcome of patients with upper gastrointestinal bleeding at the emergency department of a tertiary hospital in Nigeria. Ann Ib Postgrad Med. 2015 Dec; 13(2): 89–93.
39. Malu AO, Wali SS, Kazmi R, Macauley D, Fakunle YM. Upper gastrointestinal endoscopy in Zaria, northern Nigeria. West Afr J Med. 1990 Oct-Dec; 9(4):279-284.
40. Onyekwere CA, Hameed H, Anomneze EE, Chibututu C.Upper gastrointestinal endoscopy findings in Nigerians: a review of 170 cases in Lagos. Niger Postgrad Med J.
2008 Jun; 15(2):126-129.
41. Hawkey CJ, Talley NJ, Scheiman JM, Jones RH, Långström G, Naesdal J et al.
Maintenance treatment with esomeprazole following initial relief of non-steroidal anti-inflammatory drug-associated upper gastrointestinal symptoms: the NASA2 and SPACE2 studies. Arthritis Res Ther. 2007; 9:R17.
73
42. Cayla G, Collet JP, Silvain J, Thiefin G, Woimant F, Montalescot G.Prevalence and clinical impact of Upper Gastrointestinal Symptoms in subjects treated with low dose aspirin: the UGLA survey. Int J Cardiol. 2012 Apr 5; 156(1):69-75.
43. Hsu PI, Tsai TJ.Epidemiology of Upper Gastrointestinal Damage Associated with Low-Dose Aspirin. Curr Pharm Des. 2015; 21 (35):5049-5055.
44. Iijima, K, Shimosegawa, T.Geographic differences in low-dose aspirin-associated gastroduodenal mucosal injury.World J Gastroenterol. 2015 Jul 7; 21(25): 7709–7717.
45. Cheatum DE, Arvanitakis C, Gumpel M, Stead H, Geis GS. An endoscopic study of gastroduodenal lesions induced by non-steroidal anti-inflammatory drugs. Clinical Therapeutics. 1999, 21; 6:992-1003.
46. Yeomans ND, Lanas AI, Talley NJ, Thomson AB, Daneshjoo R, Eriksson B et al.
Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther. 2005; 22:795–801.
47. Niv Y, Battler A, Abuksis G, Gal E, Sapoznikov B, Vilkin A. Endoscopy in asymptomatic mini dose aspirin consumers. Dig Dis Sci. 2005 Jan; 50(1):78-80.
48. Griffin MR, Ray WA, Schaffner W. Nonsteroidal anti-inflammatory drug use and death from peptic ulcer in elderly persons. Ann Intern Med. 1988; 109:359–363.
49. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of non-steroidal anti-inflammatory drugs: a meta-analysis.
Ann Intern Med. 1991; 115:787-796.
50. Boissonnault WG and Meek PD. Risk factors for anti-inflammatory-drug- or aspirin-induced gastrointestinal complications in individuals receiving outpatient physical therapy services. J Orthop Sports PhysTher. 2002; 32: 510–517.
74
51. Weil J, Colin-Jones D, Langman M, Lawson D, Logan R, Murphy M et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ. 1995; 310:827–830.
52. De Abajo FJ, Garcia Rodriguez LA. Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations.
BMC Clin Pharmacol. 2001; 1:1.
53. Kelly JP, Kaufman DW, Jurgelon JM, Sheehan J, Koff RS, Shapiro S. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product.
Lancet. 1996; 348:1413–1416.
54. Hernandez-Diaz S, Garcia Rodriguez LA. Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications. BMC Med. 2006; 4:22.
55. Pritchard PJ, Kitchingman GK, Walt RP, Daneshmend TK, Hawkey CJ.Human gastric mucosal bleeding induced by low dose aspirin but not warfarin.BMJ1989; 298:493–496.
56. Sorensen HT, Mellemkjaer L, Blot WJNielsen GL, Steffensen FH, McLaughlin JK et al.
Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol. 2000;95:2218–2224
57. Skandalakis JE, Ellis H: Embryologic and anatomic basis of oesophageal surgery. Surg Clin North Am 2000; 80:85-155.
58. Orlando RC: Pathophysiology of gastroesophageal reflux disease: Esophageal epithelial resistance. In: Castell DO, Richter JE, ed. The esophagus, 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 1999:409-419.
59. Moore KL, Persaud TVN: The developing human. 7th ed. Philadelphia, WB Saunders, 2003. p 258.
60. Johnson LR: Gastrointestinal physiology. 6th ed. St. Louis, Mosby, 2001. p 75.
75
61. Laine L, Takeuchi K, Tarnawski A: Gastric mucosal defence and cytoprotection: Bench to bedside. Gastroenterology 2008; 135:41-60.
62. Oyaka J, Otaka M, Matsuhashi T,Jin M, Odashima M, Komatsu K et al: Over-expression of 70-kDa heat shock protein confers protection against monochloramine-induced gastric mucosal cell injury. Life Sci 2006; 79:300-305.
63. Taupin D, Podolsky DK: Trefoil factors initiators of mucosal healing. Nat Rev Mol Cell Biol 2003; 4:721-32
64. Flemstrom G: Active alkalinization by amphibian gastric fundic mucosa. Am J Physiol Endocrinol Metab Gastrointest Physiol 1977; 233:E1-12.
65. Atuma C, Strugala V, Allen A, Holm L. The adherent gastric mucus gel layer: Thickness and physical state in vivo. Am J Physiol Gastrointest Liver Physiol 2001; 280:G922-929.
66. Lacy ER, Ito S: Rapid epithelial restitution of the rat gastric mucosa after ethanol injury.
Lab Invest 1984; 51:573-583.
67. Tarnawski A, Stachura J, Durbin T, Sarfeh IJ, Gergely H. Increased expression of epidermal growth factor receptor during gastric ulcer healing in rats. Gastroenterology 1992; 102:695-698.
68. Yasue N, Guth PH: Role of exogenous acid and retransfusion in hemorrhagic shock-induced gastric lesions in the rat. Gastroenterology 1988; 94:1135-1143.
69. Brzozowski T, Konturek PC, Konturek SJ, Brzozowska I, Pawlik T. Role of prostaglandins in gastroprotection and gastric adaptation. J Physiol Pharmacol 2005;
56:33-55.
76
70. Szabo S: Mechanisms of gastric mucosal injury and protection. J Clin Gastroenterol 1991; 13:S21-34.
71. Redfern JS, Feldman M: Role of endogenous prostaglandins in preventing gastrointestinal ulceration: induction of ulcers by antibodies to prostaglandins.
Gastroenterology 1989; 96:596-605.
72. Needs CJ, Brooks PM.Clinical pharmacokinetics of the salicylates.Clin Pharmacokinet.
1985 Mar-Apr; 10(2):164-177.
73. Odes H, Hogan D, Ballesteros M, Wolosin JD, Koss MA, Isenberg JI. Human duodenal mucosal bicarbonate secretion. Evidence suggesting active transport under basal and stimulated conditions. Gastroenterology 1990; 98:867-872.
74. Isenberg JL, Selling JA, Hogan DL, Koss MA. Impaired proximal duodenal mucosal bicarbonate secretion. New Engl J Med 1987; 316:374-8.
75. Tanaka A, Araki H, Hase S, Hase S, Takeuchi K. Inhibition of both COX-1 and COX-2 is required for development of gastric damage in response to non-steroidal anti-inflammatory drugs. J Physiol (Paris) 2001; 95:21-27.
76. Schubert M, Peura DA. Control of gastric acid secretion in health and disease.
Gastroenterology.2008; 134:1842.
77. Lichtenberger LM, Wang ZM, Romero JJ.NSAIDS associated with Zwitterionic phospholipid: insight into the mechanism and reversal of NSAIDS gastrointestinal injury. Nat med.1995; 1:154148.
78. Hansson L, Zanchetti A, Carruthers SG,Dahlöf B, Elmfeldt D, Julius S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension:
77
principal results of the hypertension optimal treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755–1762.
79. Lanas A, Bajador E, Serrano P, Fuentes J, Carreño S, Guardia J. Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med 2000; 343: 834–839.
80. Serrano P, Lanas A, Arroyo MT, Ferreira IJ. Risk of upper gastrointestinal bleeding in patients taking low-dose aspirin for the prevention of cardiovascular diseases. Aliment Pharmacol Ther 2002; 16: 1945–1953.
81. Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005; 353: 2373–2383.
82. Hirata Y, Kataoka H, Shimura T, Mizushima T, Mizoshita T, Tanida S. Incidence of gastrointestinal bleeding in patients with cardiovascular disease: buffered aspirin versus enteric-coated aspirin. Scand J Gastroenterol. 2011; 46(7–8):803–809.
83. Gullov AL, Koefoed BG, Petersen P. Bleeding during warfarin and aspirin therapy in patients with atrial fibrillation: the AFASAK 2 study. Atrial Fibrillation Aspirin and Anticoagulation. Arch Int Med 1999; 159: 1322–1328.
84. Nielsen GL, Sorensen HT, Mellemkjoer L, Blot WJ, McLaughlin JK, Tage-Jensen U.
Risk of hospitalization resulting from upper gastrointestinal bleeding among patients taking corticosteroids: a register-based cohort study. Am J Med 2001; 111: 541–545.
85. Taylor DW, Barnett HJ, Haynes RB, Ferguson GG, Sackett DL, Thorpe KE. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial. ASA and Carotid Endarterectomy (ACE) Trial Collaborators. Lancet 1999; 353: 2179–2184.
78
86. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003; 348: 891–899.
87. Goldstein JL, Gibofsky A, Fort JG. Incidence of Endoscopic Gastroduodenal Ulcers in Subjects on 325 mg of Aspirin for Cardiovascular Prophylaxis with Placebo, a COX-2 Specific Inhibitor, or a Nonspecific NSAID; Results from a Randomized, Double-blind, Controlled Trial. Orlando, FL: American College of Rheumatology, 2003 (late breaking abstracts).
88. Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E et al.
Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications:
randomised controlled trial. Lancet 2004; 364: 665–674.
89. The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 1988; 351: 233–241.
90. Johnson WC, Williford WO, Department of Veterans Affairs Cooperative Study #362.
Benefits, morbidity, and mortality associated with long-term administration of oral anticoagulant therapy to patients with peripheral arterial bypass procedures: a prospective randomized study. J Vasc Surg 2002; 35: 413–421.
91. Lanas A, Fuentes J, Benito R, Serrano P, Bajador E, Sainz R. Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin.
Aliment Pharmacol Ther. 2002; 16:779–786.
79
92. Stack WA, Atherton JC, Hawkey GM, Logan RF, Hawkey CJ. Interactions between Helicobacter pylori and other risk factors for peptic ulcer bleeding. Aliment Pharmacol Ther. 2002; 16:497–506.
93. El-Omar EM: Mechanisms of increased acid secretion after eradication of Helicobacter pylori infection. Gut 2006; 55:144-146.
94. Vakil N, Talley NJ, Stolte M, Sundin O, Junghard E, Bolling-Sternevald et al: Patterns of gastritis and the effect of eradicating Helicobacter pylori on gastro-oesophageal reflux disease in Western patients with non-ulcer dyspepsia. Aliment Pharmacol Ther 2006;
24:55-63.
95. El-Omar EM, Oien K, El-Nujumi A, Gillen D, Wirz A, Dahill S et al: Helicobacter pylori infection and chronic gastric acid hyposecretion. Gastroenterology 1997; 113:15-24.
96. Malfertheiner P, Peitz U: The interplay between Helicobacter pylori, gastro-oesophageal reflux disease, and intestinal metaplasia. Gut 2005; 54(Suppl 1):i13-20.
97. Saad R, Chey WD. A clinician’s guide to managing Helicobacter pylori infection. Cleve Clin J Med. 2005; 72(2):109–110.
98. Malfertheiner P, Chan FK, McColl KE. Peptic ulcer disease. Lancet. 2009;
374(9699):1449–1461.
99. Hasni S, Ippolito A, Illei GG. Helicobacter pylori and autoimmune diseases. Oral Dis.
2011; 17(7):621–627.
100. S Mustapha, M Bolori, N Ajayi, H Nggada, U Pindiga, W Gashau, M Khalil. Endoscopic Findings and the Frequency of Helicobacter Pylori among Dyspeptic Patients in North-Eastern Nigeria.The Internet Journal of Gastroenterology. 2006 Volume 6 Number 1.
80
101. Ndububa DA, Agbakwuru AE, Adebayo RA, Olasode BJ, Olaomi OO, Adeosun OA, et al. Upper gastrointestinal findings and incidence of Helicobacter pylori infection among Nigerian patients with dyspepsia West Afr J Med. 2001 Apr-Jun;20(2):140-145.
102. Jemilohun AC, Otegbayo JA, Ola SO, Oluwasola OA, Akere A.Prevalence of helicobacter pylori among Nigerian patients with dyspepsia in Ibadan. Pan Afr Med J.
2010; 6: 18.
103. Carpani de Kaski M, Rentsch R, Levi S, Hodgson HJ. Corticosteroids reduce regenerative repair of epithelium in experimental gastric ulcers. Gut. 1995; 37:613–616.
104. García Rodríguez LA, Lin KJ, Hernández-Díaz S, Johansson S. Risk of upper gastrointestinal bleeding with low-dose acetylsalicylic acid alone and in combination with clopidogrel and other medications. Circulation. 2011; 123:1108–1115.
105. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B et al.
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis: VIGOR Study Group. N Engl J Med. 2000; 343: 1520–1528.
106. Rahme E, Bardou M, Dasgupta K, Tobouti Y, Barkun AN. Gastrointestinal effects of rofecoxib and celecoxib versus NSAIDs among patients on low dose aspirin.
Gastroenterology 2004; 126 (Suppl. 2): A-1–2.
107. Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin:
meta-analysis. BMJ 2000; 321: 1183–1187.
108. McQuaid KR, Laine L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am J Med; 2006; 119: 624–
638.
81
109. Gluckman TJ, Baranowski B, Ashen MD, Henrikson CA, McAllister M, Braunstein JB et al. A practical and evidence-based approach to cardiovascular disease risk reduction.
Arch Intern Med. 2004; 164:1490–1500.
110. Lanas A, Garcia-Rodriguez LA, Arroyo MT, Gomollón F, Feu F, González-Pérez A et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclooxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut. 2006; 55:1731–8.
111. Bhatt DL, Fox KA, Hacke W,Berger PB, Black HR, Boden WE et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med.
2006; 354:1706–17.
112. Ma L, Elliott SN, Cirino G, Buret A, Ignarro LJ, Wallace JL. Platelets modulate gastric ulcer healing: role of endostatin and vascular endothelial growth factor release. Proc Natl Acad Sci U S A. 2001; 98:6470–6475.
113. Sheikh RA, Romano PS, Prindiville TP, Yasmeen S, Trudeau W. Endoscopic evidence of mucosal injury in patients taking ticlopidine compared with patients taking aspirin/non-steroidal anti-inflammatory drugs and controls. J Clin Gastroenterol. 2002;
34:529–532.
114. Lanas A, Garcia-Rodriguez LA, Arroyo MT, Bujanda L, Gomollón F, Forné M et al.
Effect of anti-secretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am J Gastroenterol. 2007; 102:507–515.
115. Ko JK, Cho CH.Alcohol drinking and cigarette smoking: a "partner" for gastric ulceration.Zhonghua Yi Xue Za Zhi (Taipei). 2000 Dec; 63(12):845-854.
82
116. Bujanda L.The effects of alcohol consumption upon the gastrointestinal tract.Am J Gastroenterol. 2000 Dec; 95(12):3374-3382.
117. Sostres C, Gargallo CJ, Arroyo MT, Lanas A: Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract. Best Pract Res Clin Gastroenterol 2010, 24:121-132.
118. Jensen MP, Turner JA, Romano JM, Fisher LD. Comparative reliability and validity of chronic pain intensity measures. Pain. 1999; 83:157–162.
119. Jensen MP, Karoly P. Self-report scales and procedures for assessing pain in adults. In:
Turk DC, Melzack R, eds. Handbook of Pain Assessment. Second edn. New York:
Guilford Press; 2001:15–34.
120. Hegedusa O, RydeÂnb J, Rehnberga A, Nilssonb S, HellstroÈma PM. Validated accuracy of a novel urea breath test for rapid Helicobacter pylori detection and in-of®ce analysis. European Journal of gastroenterology & Hepatology 2002, 14:1-8.
121. Boer W A, Alfen CV, Ryden J. Validation of a new portable near patient urea breath test;
the Heliprobe system. European Helicobacter Study Group, XVIth International Workshop, Sep 2003, Sweden.
122. Banerjee S, Cash DB, Dominitz JA, Baron TH, Anderson MA, Ben-Menachem T et al.
The role of endoscopy in the management of patients with peptic ulcer disease.
GastrointestEndosc 2010; 71:663.
123. Fisher RA. The logic of inductive inference (with discussion).Journal of Royal Statistical Society. 1935; 98:39–82.
83
124. Miri-Dashe T, Osawe S, Tokdung M, Daniel N, Choji R P, Mamman I et al.
Comprehensive Reference Ranges for Haematology and Clinical Chemistry Laboratory Parameters Derived from Normal Nigerian Adults. PLoS One. 2014; 9(6): e100601.
125. DuhS, Cook J D. Laboratory references range values.
http://www.stedmansonline.com/webFiles/Dict-Stedmans28/APP17. Page App110. Cited on the 10/06/14.
126. Silagy CA, McNeil JJ, Donnan GA, Tonkin AM, Worsam B, Campion K. Adverse effects of low-dose aspirin in a healthy elderly population. Clin Pharmacol Ther. 1993 Jul;
54(1):84-9.
127. Adeniyi BA, Otegbayo JA, Lawal TO, Oluwasola AO, Odaibo GN, Okolo C et al.
Prevalence of Helicobacter pylori infection among dyspepsia patients in Ibadan, South West Nigeria. African Journal of Microbiology Research Vol. 6(14), pp. 3399-3402.
128. Iijima K, Ara N, Abe Y, Koike T, Iwabuchi T, Shinkai H, Uno K, Endo H, Asano N, Shimosegawa T. Biphasic effects of H. pylori infection on low-dose aspirin-induced gastropathy depending on the gastric acid secretion level. J Gastroenterol. 2012;
47:1290–1297.
129. Watanabe M, Kawai T, Takata Y, Yamashina A. Gastric mucosal damage evaluated by transnasal endoscopy and QOL assessments in ischemic heart disease patients receiving low-dose aspirin. Intern Med. 2011; 50:539–544.
130. Iijima K, Koike T, Ara N, Nakagawa K, Kondo Y, Uno K, Hatta W, Asano N, Imatani A, Shimosegawa T. Identification of a high-risk group for low-dose aspirin-induced gastropathy by measuring serum pepsinogen in H. pylori-infected subjects. J Gastroenterol. 2015; 50:305–312.